Nozar Dorestan
1, Mohammad Bahadoram
2, Mohammadreza Khosravi
3, Sara Bahadoram
4, Mohammad Davoodi
5, Maedeh Barahman
6*1 Department of Surgery, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 Medical Student Research Committee and Social Determinant of Health Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3 Cancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
4 Department of Pediatrics, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
5 Department of Radiology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
6 Department of Radiation Oncology, Firoozgar Hospital, Firoozgar Clinical Research Development Center (FCRDC), Iran University of Medical Sciences (IUMS), Tehran, Iran
Abstract
Diabetes therapies were associated with either a reduced or increased risk of cancer. There are
continuous discussions about a possible protective action of metformin. In fact, metformin, a
commonly consumed anti-diabetic medication has an ameliorative impact on some cancers
by direct (preventing cell growth and apoptosis) and indirect (increasing insulin sensitivity)
effects. Observational reports have suggested which metformin reduces the incidence of
few common cancers. In general, metformin is an extensively recommended anti-diabetic
medication with a recognized ability coupled with a satisfactory and safety profile and
inexpensive. This review article considers reduction and protective abilities of metformin on
cancers especially prostate, liver, breast, lung, and colon cancer.
Implication for health policy/practice/research/medical education:
Metformin, a commonly consumed anti-diabetic medication, has an ameliorative impact on some cancers by direct (preventing
cell growth and apoptosis) and indirect (increasing insulin sensitivity) effects.
Please cite this paper as: Dorestan N, Bahadoram M, Khosravi M, Bahadoram S, Davoodi M, Barahman M. Beyond
renoprotective impact; ameliorative effects of metformin on malignancies. J Nephropharmacol. 2017;7(2):50-54.